ALDX Aldeyra Therapeutics, Inc.

4.75
+0.00  (0%)
Previous Close 4.75
Open 4.70
Price To book 2.57
Market Cap 29.66M
Shares 6,245,000
Volume 42,183
Short Ratio 1.73
Av. Daily Volume 83,034

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due 3Q 2017.
ADX-102
Dry eye syndrome
Phase 2b enrollment initiation announced February 7, 2017. Data due June 2017.
ADX-102
Allergic conjunctivitis
Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
ADX-102
Noninfectious anterior uveitis
Phase 3 trial initial data due 2H 2018.
ADX-102
Sjögren-Larsson Syndrome (SLS)

Latest News

  1. Roche (RHHBY) Presents Positive Data on IPF Drug Esbriet
  2. Horizon (HZNP) Sells European Rights for Procysbi & Quinsair
  3. Celgene (CELG) Multiple Sclerosis Drug Meets Primary Endpoint
  4. Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting
  5. Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results
  6. Investor Network: Aldeyra Therapeutics, Inc. to Host Earnings Call
  7. Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results
  8. Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial
  9. Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome
  10. Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
  11. Aldeyra Therapeutics Reports Full Year 2016 Financial Results
  12. Aldeyra Therapeutics Schedules Webcast and Conference Call for Full Year 2016 Financial Results
  13. Aldeyra Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
  14. Executives at Crane Manufacturer Buy Shares Amid Optimism about Infrastructure Spending Boost, Plus Other Insider Trading
  15. Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome
  16. Aldeyra Therapeutics, Inc. Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
  17. Aldeyra Therapeutics, Inc. Prices Public Offering of Common Stock
  18. Aldeyra Therapeutics, Inc. Proposes Public Offering of Common Stock
  19. Aldeyra Therapeutics Announces First Patient Enrolled in Allergic Conjunctivitis Phase 2b Clinical Trial
  20. Aldeyra Therapeutics to Participate at the 2017 Rare Disease, Biopharma One-on-One Day